On February 13, 2020 H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., reported the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical stage assets (Press release, H3 Biomedicine, FEB 19, 2020, View Source [SID1234554519]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"H3 is at a pivotal stage of growth. The breadth of our precision medicine-driven discovery and clinical R&D requires a CMO with vast scientific knowledge and leadership expertise," said Lihua Yu, PhD, President and Chief Data Science Officer, H3. "Dr. Gualberto possesses more than 20 years of experience in developing clinical assets at multiple biopharma companies. His deep acumen and proven success will be instrumental as we work toward our goal of delivering clinically meaningful outcomes for patients with highly unmet medical needs."

Most recently Dr. Gualberto served as co-founder and CMO at Kura Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. At Kura, Dr. Gualberto led the discovery of the mechanism of action and clinical proof-of-concept of farnesyl transferase inhibitors as well as bringing a pipeline of new agents to the clinic. Prior to Kura, Dr. Gualberto held positions of increasing responsibility at EMD Serono, a subsidiary of Merck KGaA, Takeda and Pfizer. Dr. Gualberto received his MD and PhD degrees from the University of Seville in Spain. He also completed several fellowships in the field of Molecular Pathology, was a member of the Berkeley National Laboratory and held academic faculty positions at Case Western Reserve University and Brown University.

"Our entire organization is thrilled by the appointment of Dr. Gualberto to the position of CMO here at H3," commented Terushige Iike, Chief Executive Officer of H3 and President of the Oncology Business Group at Eisai Co., Ltd. "We eagerly anticipate the progress we will make as a company with Antonio leading our global clinical research & development organization. His expertise and wide experience will be invaluable to H3 as we advance our pipeline of multiple clinical stage assets."

"With the umbrella of support of a global pharmaceutical company such as Eisai, H3 is uniquely positioned as a clinical stage biopharmaceutical company. In creating a prolific drug discovery engine and partnership platform, H3 has shown itself to be a leader in the development of new clinical programs," said Dr. Gualberto. "H3 has a first-rate team that is highly regarded in the oncology community with fantastic discovery and development capabilities, and I look forward to working closely with our entire organization."

On February 19, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 3,478,261 common shares at a purchase price of $1.29375 per common share in a registered direct offering priced at-the-market under Nasdaq rules (Press release, AEterna Zentaris, FEB 19, 2020, View Source [SID1234554539]). The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aeterna Zentaris will also issue to the purchasers unregistered warrants to purchase up to an aggregate of 2,608,696 common shares. The warrants will be exercisable for a period of five and one-half years, exercisable immediately following the issuance date and have an exercise price of $1.20 per common share.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The registered direct offering and concurrent private placement is expected to close on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

The common shares described above (but not the warrants or the common shares underlying the warrants) are being offered by Aeterna Zentaris pursuant to a "shelf" registration statement on Form F-3 (File No. 333-232935), which was previously declared effective by the U.S. Securities and Exchange Commission ("SEC") on August 15, 2019. Such common shares may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

A prospectus supplement relating to the common shares will be filed by Aeterna with the SEC. When filed with the SEC, copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering, may be obtained at the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or by email at [email protected].

The warrants described above were offered in a private placement pursuant to an exemption from the Securities Act of 1933, as amended (the "Act"), and along with the common shares issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the common shares or the warrants in connection with the offering.

On February 19, 2020 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported that it will participate in the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020. Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive vice president and chief financial officer, will present at 10:20 a.m. Central time (Press release, AbbVie, FEB 19, 2020, https://news.abbvie.com/news/press-releases/abbvie-to-present-at-cowen-40th-annual-health-care-conference.htm [SID1234554487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On February 19, 2020 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences (Press release, Kura Oncology, FEB 19, 2020, View Source [SID1234554504]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the SVB Leerink 9th Annual Global Healthcare Conference in New York at 11:30 a.m. ET / 8:30 a.m. PT on February 26, 2020;

A presentation at the Cowen 40th Annual Health Care Conference in Boston at 8 a.m. ET / 5 a.m. PT on March 3, 2020; and

A presentation at the Oppenheimer 30th Annual Healthcare Conference in New York at 10:20 a.m. ET / 7:20 a.m. PT on March 17, 2020.
Live audio webcasts of the fireside chat and presentations will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

On February 19, 2020 Humanetics Corporation (Humanetics) reported that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets related to the manufacture of the active pharmaceutical ingredient (API) in BIO 300, a clinical stage drug being developed by Humanetics for oncology and biodefense applications (Press release, Humanetics, FEB 19, 2020, View Source [SID1234554521]). DSM developed and patented a method to produce a highly pure form of the API.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods, regulatory filings, and a large number of nonclinical and clinical safety studies. Humanetics plans to transfer the manufacturing process to a site in the United States.

BIO 300 is a clinical stage drug under development to protect normal tissues from the harm caused by radiation. The drug’s radioprotective effects were originally discovered by researchers within the Department of Defense at the Armed Forces Radiobiology Research Institute. Humanetics has received significant federal funding to continue advancement of BIO 300 toward FDA approval. Humanetics has also initiated clinical studies for the use of BIO 300 to reduce the toxicity of radiation used in cancer treatment.

"We have had a long and successful collaboration with DSM, and we are excited to add these important assets to our BIO 300 program," said John Dykstra, Chief Operating Officer at Humanetics. "The assets we are acquiring from DSM will allow us to control and protect our entire manufacturing process from start to finish."